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Abstract
Nitric oxide (NO) and cyclooxygenase-derived prostaglandins, such as prostacyclin (PGI2), are involved in vascular homeostasis. To better
understand the reciprocal role of both NO and PGI on myocardial infarction in the rat, we have investigated the cardioprotective effect of nitro-
n
c
(
V
c
c
b
c
a
p
m
©
K
1
t
h
m
p
a
r
d
t
a
1
d2
aproxen, isosorbide dinitrate (ISDN), l-arginine, defibrotide and naproxen. In this study, male Wistar rats were treated orally once a day for 5
onsecutive days with the compounds under investigation and then, under anesthesia, the animals were subjected to acute myocardial ischemia
30 min) and reperfusion (120 min). Systemic blood pressure, left ventricular pressure and related parameters of cardiac mechanics were recorded.
entricular arrhythmias and infarct size of the left ventricular wall were also evaluated. Furthermore, cardiac myeloperoxidase (MPO) and plasma
reatine phosphokinase (CPK) activities were determined. Defibrotide, nitro-naproxen, ISDN and l-arginine all provided a cardioprotection
haracterized by significant prevention of arrhythmias with high survival rate of the rats. Infarct size restriction was paralleled by reduction of
oth cardiac MPO and plasma CK. Cardioprotection of nitro-naproxen, ISDN and l-arginine involve nitrites/nitrates and PGI2-increased in the
irculation associated to a reduction of thromboxane B2 (TXB2) in the blood. Defibrotide displays a cardioprotection by increasing PGI2 release
nd by reducing TXB2 in the blood. Naproxen was devoid a lower protecting activity on myocardial infarction, and PGI2 inhibition may have
layed a critical role in this context. The results suggested that the increase of both NO and PGI2 brings about a cascade of integrated cellular and
olecular events which are of paramount importance in prevention of myocardial ischemic insult.
2006 Elsevier Ltd. All rights reserved.
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. Introduction
Over the last 2 decades, coronary reperfusion therapy with
hrombolytic and fibrinolytic agents and coronary angioplasty
as become established procedures for the management of acute
yocardial infarction [1]. However, blood flow restoration to
reviously ischemic myocardium is responsible for injury to
viable myocardium and for a “mismatch” between flow and
ecovery of mechanical function even when no irreversible
amage has been reported [2]. In this instance, the persis-
ent ventricular dysfunction may lead to develop heart failure
nd progressive ventricular remodeling. Several studies have
∗ Corresponding author. Tel.: +39 02 50317060; fax: +39 02 50317058.
E-mail address: giuseppe.rossoni@unimi.it (G. Rossoni).
linked neutrophils to reperfusion injury since depletion of neu-
trophils is correlated with less cellular damage after ischemia-
reperfusion [3]. Endothelial dysfunction is associated with a
sequence of increased adhesiveness of neutrophils, increase in
neutrophils–endothelial cell interactions, release of inflamma-
tory mediators (e.g. oxygen free radicals and platelet-activating
factor), activation of circulating neutrophils, release of a vari-
ety of harmful substances (cytokines, leukotrienes and pro-
teases) and tissue injury and necrosis [4,5]. In the light of
these events leading to a dysfunction of the coronary endothe-
lium, research should focus on an adjunctive therapy that may
limit post-ischemic ventricular dysfunction and speed func-
tional recovery [6]. Potential candidates include nitric oxide
(NO) or NO-donors such as nitroglycerine [7], and also the
nitro-derivative of aspirin (nitro-aspirin) and naproxen (nitro-
naproxen) should be considered of some therapeutical interest.
043-6618/$ – see front matter © 2006 Elsevier Ltd. All rights reserved.
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360 G. Rossoni et al. / Pharmacological Research 53 (2006) 359–366
These two nitro-derivatives of conventional non-steroidal anti-
inflammatory drugs (NSAIDs), synthetized to reduce or abolish
their gastrointestinal toxicity [8], have been reported to display
cardioprotection in perfused rabbit heart submitted to global
ischemia-reperfusion. Both nitro-aspirin and nitro-naproxen, by
donation of NO, bring about a marked reduction of ventricular
contracture during ischemia with remarkable improvement of
left ventricular developed pressure at reperfusion [9–11].
Many of endothelium-derived factors like NO, prostacyclin
(PGI2) and endothelim-dependent hyperpolarization (EDHF)
share a number of common functions, although they are part
of different metabolic systems [12–16]. Pharmacological inter-
ventions of one pathway could result in a cross-modulation of the
other, but the relevance of this interaction is often controversial
[17,18]. Although the NO- and eicosanoid-producing pathways
have been studied extensively, particularly in an inflammatory
focus [19], the investigation on the ability of different NO-
donors and the potent PGI2-releaser defibrotide to control the
myocardial infarction progression may further contribute to
better understand the reciprocal role of NO and PGI2 in car-
dioprotection.
2. Materials and methods
2.1. Animals
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PGF1 samples) tubes. The samples were centrifuged for 15 min
(2500 × g at 4 ◦C) and aliquots of the supernatant were removed,
and stored frozen at −80 ◦C until assayed. After purification
according to the manufacturer’s instructions, plasma TXB2 and
6-keto-PGF1 levels were measured using enzyme immunoas-
say kits. Furthermore, plasma NOx levels were determined
by a colorimetric microplate assay kit that uses the Greiss
reagent.
2.3. Myocardial ischemia/reperfusion (MI/R) in
anaesthetized rats
2.3.1. Experimental design
For MI/R experiments, rats were randomly assigned to
seven different groups of at least 14 animals each and
treated with naproxen (50 mg kg−1), defibrotide (200 mg kg−1),
nitro-naproxen (80 mg kg−1), ISDN (40 mg kg−1) or l-arginine
(25 mg kg−1). All drugs, dissolved in PEG 400 (vehicle), were
administered orally by gavage (volume, 2 ml kg−1) once a day
for 5 consecutive days. At the fifth day, the treatment was per-
formed 1 h before anaesthesia. The doses used for naproxen,
defibrotide, nitro-naproxen, ISDN or l-arginine were selected
referring to the results obtained in preliminary experiment (see
above section). At these doses the increase of NOx in the cir-
culation was in the same range (see Table 1). Defibrotide has
been utilized at 200 mg kg−1 since at this regimen a remark-
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uMale Wistar rats (Charles River Italia, Calco, LC, Italy),
eighing 260–280 g were used. The animals were housed in a
onditioned environment (22 ± 1 ◦C, 55 ± 5% relative humidity,
2-h light and 12-h darkness cycle) and were given free access to
ood and tap water. The investigation conforms with the Guide
or the Care and Use of Laboratory Animals published by the
.S. National Institutes for Health (NIH Publication No. 85–23,
evised 1996).
.2. Preliminary experiments
.2.1. Experimental design
In these series of experiments different doses of naproxen
12.5, 25, 50 mg kg−1), defibrotide (50, 100, 200 mg kg−1),
itro-naproxen (20, 40, 80 mg kg−1), isosorbide dinitrate
ISDN; 10, 20, 40 mg kg−1) and l-arginine (6.25, 12.5,
5 mg kg−1) were dissolved in polyethylene glycol 400 (PEG
00; vehicle) and administered orally by gavage (volume,
ml kg−1) once a day for 5 consecutive days to 16 different
roups of four animals each. Their capacity to reduce plasma
hromboxane B2 (TXB2) levels, and to increase both NO (as
itrates/nitrites; NOx) and PGI2 (as 6-keto-prostaglandin F1,
-keto-PGF1) levels has been evaluated in the circulating blood.
.2.2. Measurement of plasma TXB2, 6-keto-PGF1α and
Ox levels
Blood samples for plasma TXB2, 6-keto-PGF1 and NOx
easurements were withdrawn via cardiac puncture from
he anaesthetized animals (thiopentone sodium, Pentothal®,
g kg−1 i.p.), collected with heparinized syringes and put into
ndomethacin (100 mmol l−1)-rinsed (for TXB2 and 6-keto-ble release of PGI2 was observed. The length of treatment was
stablished in terms of once a day for 5 consecutive days since
he increase of both NOx and PGI2 into the blood was maximal
nly after 4 days of treatment (data not shown).
.3.2. Surgical preparation
Rats were anaesthetized with thiopentone sodium
Pentothal®, 60 mg kg−1 i.p.), placed in the supine posi-
ion on a table and the body temperature was maintained
t 38 ± 1 ◦C by means of a heating pad. Animals were tra-
heotomized, intubated and ventilated with room air using a
espirator for small rodents (model 7025; Ugo Basile, Comerio,
arese, Italy) with a stroke volume of 10 ml kg−1 and a rate
f 60–65 strokes min−1 to maintain normal pH (7.35–7.45),
O2 (80–110 mmHg) and pCO2 (25–40 mmHg) parameters.
atheters (polyethylene tubing; i.d. 0.58 mm, o.d. 0.965 mm)
ere inserted into the left femoral artery and right jugular vein
or the measurements of blood pressure (BP) and drug/vehicle
dministration, respectively. A 2F micromanometer catheter
ith one high-fidelity pressure sensor (model SPR-249; Millar
nstruments Inc., Houston, Texas) was introduced via the
solated right carotid artery into the left ventricle and was
sed to measure the left ventricular pressure (LVP). The
ero pressure baseline was obtained by placing the pressure
ensor in 37 ◦C physiological saline prior to measurements.
urthermore, subdermal platinum electrodes were placed
o allow the determination of a lead II electrocardiogram
ECG). According to the procedure described by Himori and
atsuura [20], the chest was opened by a left thoracotomy at
he fourth or fifth intercostal space, the ribs were gently spread
sing a small-sized retractor and the heart was exposed. After
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Table 1
Effect of naproxen, defibrotide, nitro-naproxen, isosorbide dinitrate (ISDN)
and l-arginine on plasma nitrites/nitrates (NOx), thromboxane B2 (TXB2) and
prostacyclin (as 6-keto-PGF1) levels in male Wistar rats
Treatment
(mg kg−1)
Plasma NOx
(M)
Plasma TXB2
(pg ml−1)
Plasma 6-keto-PGF1
(ng ml−1)
Vehicle
– 32.7 ± 3.4 281.7 ± 23.4 0.38 ± 0.04
Naproxen
12.5 25.9 ± 4.2 189.2 ± 14.5* 0.32 ± 0.05
25 31.0 ± 1.7 58.5 ± 11.2*** 0.24 ± 0.03*
50 22.8 ± 5.5 29.6 ± 4.8*** 0.11 ± 0.02**
Defibrotide
50 42.3 ± 5.8 241.5 ± 26.4 1.45 ± 0.23**
100 50.6 ± 3.9* 179.3 ± 18.2* 3.97 ± 0.52***
200 82.3 ± 6.8** 135.4 ± 17.8** 5.72 ± 0.78***
Nitro-naproxen
20 53.3 ± 4.2* 228.1 ± 31.2 0.45 ± 0.05
40 106.1 ± 9.4** 148.5 ± 15.6** 0.55 ± 0.08
80 143.6 ± 11.5*** 69.6 ± 8.4*** 0.53 ± 0.06
ISDN
10 74.8 ± 9.5** 249.7 ± 20.1 0.45 ± 0.03
20 122.3 ± 16.3*** 178.9 ± 36.5* 0.91 ± 0.06*
40 181.7 ± 15.4*** 161.6 ± 24.3* 1.23 ± 0.04**
l-Arginine
6.2 63.4 ± 9.4* 251.0 ± 23.6 0.79 ± 0.04*
12.5 111.7 ± 13.4** 197.6 ± 18.2* 1.40 ± 0.12**
25 176.2 ± 16.4*** 148.2 ± 10.9** 1.84 ± 0.06***
Vehicle (PEG 400, 2 ml kg−1), naproxen, defibrotide, nitro-naproxen, ISDN and
l-arginine were administered orally once a day for 5 consecutive days. Data are
expressed as mean ± S.E.M. (n = 4 animal each dose/group.)
* P < 0.05 vs. vehicle-treated rats.
** P < 0.01 vs. vehicle-treated rats.
*** P < 0.001 vs. vehicle-treated rats.
incision of the pericardium to allow access to the left main
coronary artery (LCA), the heart was quickly removed from the
thoracic cavity and inverted. An atraumatic needle (no. FS-2;
Ethicon, Pratica di Mare, Rome, Italy) with a thin silk thread
(no. 5-0) was used for the ligature. The needle was inserted
(approximately 0.5 mm) into the myocardium 2–3 mm away
from the origin of the LCA (just beneath the left auricular
appendage). The thread was then made into an overhand knot
(an occluder): two other threads were tied to the main knot
(releasers). The heart was returned quickly to the thoracic
cavity and the tips of the suture used to produce the coronary
ligation were exteriorised through the chest wall. The whole
surgical procedure described above took about 10–12 min and
at the end the animals were allowed to stabilize for 30 min
before LCA-ligation. The coronary artery was occluded at time
0 for 30 min by tightening of the occluder. This was associated
with the typical electrocardiographic (ST-segment elevation
and increase in R-wave amplitude) and hemodynamic (fall
in BP) changes due to myocardial ischemia. After 30 min of
LCA-ligation, the occluder was re-opened and the heart was
reperfused for 120 min. At the end of this period the heart
was removed for infarct size estimation and myeloperoxidase
(MPO) determination.
2.3.3. Hemodynamic measurement
Throughout the experiments, using the signals of both BP
and LVP transmitted continuously to the pressure modules
(model Mc Lab-4E; AD Instruments, Hastings, UK), systolic
and diastolic arterial pressure (DAP), and mean arterial pres-
sure (MAP) were obtained. The following parameters related to
cardiac mechanics were also determined: left ventricular sys-
tolic pressure (LVSP), left ventricular end-diastolic pressure
(LVEDP), left ventricular developed pressure (LVDevP) and the
maximal velocity rate of pressure development of left ventricle
(LVdP/dtmax). Furthermore, the ECG (lead II) was recorded with
a Cardioline apparatus (model Delta-1; Remco Italia, Milan,
Italy) and the signals were continuously transmitted into Mc
Lab-4E ECG module (AD Instruments). All the data obtained
from each module of the system were analyzed with computer
software Charter Windows 3.5 (AD Instruments). The pressure
rate index (PRI), an indicator of myocardial oxygen consump-
tion [21], was also calculated as the product of MAP and heart
rate (HR).
2.3.4. Assessment of arrhythmia
Using the ECG signals, ventricular arrhythmia (ensuing dur-
ing the total 30 min of LCA-occlusion and the first 10 min of
LCA-reperfusion) were assessed as described by Clark et al. [22]
and in accordance with the definitions reported in the Lambeth
Conventions [23]. In survivor rats the total number of ventricu-
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aar premature beats (VPBs), including singles, bigeminy, salvos
nd ventricular tachycardia (VT; defined as four or more consec-
tive VPBs) was counted. The incidence and duration of VT and
entricular fibrillation (VF) were also recorded along with the
ortality (due to sustained VF, defined as continuous VF persist-
ng for at last 3 min). Rats were excluded from the final analysis
f any of the following occurred: arrhythmias prior to LCA-
cclusion; cardiac failure (defined as a profound reduction in
rterial pressure, approaching zero within the first 5 min follow-
ng LCA-occlusion, usually accompanied by A-V block, which
s probably due to the ligature being placed too deeply such that
he septal branch of the LCA is also occluded); no evidence
f ischemia after tying the ligature (changes in either the ST-
egment or R-wave amplitude; arrhythmia); MAP < 60 mmHg
rior to LCA-occlusion. Any rats which were excluded were
eplaced immediately.
.3.5. Determination of area at risk and infarct size
The area at risk and infarct size were evaluated with Evans
lue dye and the triphenyltetrazoliun chloride, respectively [22].
n brief, at the end of the 2 h-reperfusion period, the liga-
ure around the LCA was retightened and 1 ml Evans blue
ye (3%, w/v) was injected intravenously into the jugular
ein to delineate ischemic (area at risk) and non-ischemic
yocardium (area not at risk). The Evans blue solution stains
he perfused myocardium, while the non-perfused myocardium
emains uncoloured. The rat was euthanized with a 15% potas-
ium chloride solution and the heart was rapidly excised, rinsed
nd blotted dry. After removing the atria, right ventricle wall
nd the major blood vessels, the left ventricle was sliced par-
llel to the atrioventricular groove in 3 mm-thick sections. The
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area at risk of the left ventricle (unstained portion) was sep-
arated from the area not at risk of the left ventricle (stained
portion). The area at risk was again sectioned into 1 mm-thick
slices and incubated in a 1% (w/v) solution of the triphenylte-
trazoliun chloride stain in 20 mM phosphate buffer (pH 7.4) at
37 ◦C for 20 min. The tetrazolium dye forms a blue formazan
complex in the presence of coenzymes and dehydrogenases [24].
The irreversibly injured necrotic portion of the myocardium,
which did not stain, was separated from the stained portion (i.e.,
ischemic but non-necrotic area at risk). All portions of the left
ventricular myocardium were weighed and stored at −70 ◦C for
subsequent assay of MPO activity. Infarct size was expressed as
a percentage of the area at risk.
2.3.6. Cardiac MPO activity
MPO activity was evaluated as an index of neutrophils accu-
mulation in jeopardized tissue because it correlates closely with
the number of polymorphonuclear leukocytes present in the
heart [25]. This enzyme was determined in the two portions
of the left ventricle (area not at risk and area at risk) using
a specific assay for this enzyme [26]. Myocardial tissue sam-
ples were first homogenized in a 0.5% (w/v) hexadecyltrimethyl
ammonium bromide solubilized in 50 mM potassium phosphate
buffer (pH 6.0) using a Polytron homogenizer (Ika Ultra-Turrax
T25; Janke & Kunkel GmbH Co., Staufen, KG, Germany)
for 30 s (15 + 15 s) at 7000 rev min−1. Homogenates were cen-
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when appropriate, a Dunnet’s multiple comparison procedure
(GraphPad Prism; GraphPad, San Diego, CA). Incidences of VT
and VF were compared by Fisher-Irwin (chi-squared with Yates
correction) test. Analysis of mortality rate was carried out with
the analysis of LogLikelihood for categorical data and either
Pearson or Likelihood-Ratio 2 tests [28]. Body weight, heart
weight, left ventricular weight, area at risk and infarct size were
compared with a one way analysis of variance (ANOVA) fol-
lowed, when ANOVA was significant, by a Tukey-Kramer test
for multiple comparison. A value of P < 0.05 was considered
statistically significant.
2.5. Drugs
The following drugs were used: naproxen, l-arginine, Evans
blue, PEG 400, hexadecyltrimethyl ammonium bromide, O-
dianisidine dihydrochloride (Sigma Chemical Co., St. Louis,
MO, USA); thiopentone sodium (Abbott, Campoverde, Latina,
Italy), defibrotide (Crinos, Villaguardia, Como, Italy), nitro-
naproxen (NicOx S.A., Valbonne, Sophia Antipolis, France),
ISDN (ICN Biomedicals Inc., Irvine, CA, USA); kit for CPK
determination (Boehringer-Mannheim Italia, Milan, Italy); kits
for TXB2, 6-keto-PGF1 and NOx determinations (Cayman
Chemical, Ann Arbor, MI, USA).
3. Results
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vrifuged at 12,500 × g at 2 ◦C for 30 min on a Optima Ultra
ltracentrifuge (Beckman, Palo Alto, CA). The supernatant was
ollected and reacted with a solution of O-dianisidine dihy-
rochloride (0.167 mg ml−1) and 0.0005% hydrogen peroxide
n 50 mM potassium phosphate buffer (pH 6.0). The rate of
hange in absorbance was measured spectrophotometrically at
60 nm (model Lambda16, Perkin Elmer Italia, Monza, Milan,
taly). MPO standard curve (2.5–0.08 U ml−1) was included in
ach assay. One unit of MPO activity was defined as the quan-
ity of enzyme degrading 1M of peroxide min−1 at 25 ◦C and
xpressed in U g−1 tissue.
.3.7. Plasma creatine phosphokinase (CPK) activity
CPK activity was determined in plasma collected immedi-
tely before LCA-occlusion (time 0 min), at the end of 30 min of
CA-occlusion period (time 30 min) and at the end of 120 min
f LCA-reperfusion period (time 150 min). In brief, samples
0.5 ml) of arterial blood were drawn from the femoral artery
atheter. The blood was centrifuged for 15 min at 2400 × g at
◦C and the plasma supernatant was removed and stored frozen
t −20 ◦C until assayed. Plasma was processed for CPK activity
27] using a commercially available kit and the total amount was
etermined on a spectrophotometer at a wavelength of 340 nm
Model Lambda16, Perkin Elmer Italia, Monza, Milan, Italy).
PK activity was expressed in U l−1 plasma.
.4. Statistical analysis
Except for the incidence of VT, VF and mortality rate, all val-
es are expressed as means ± S.E. Differences between means
ere compared by Student’s two-tailed unpaired t-test with,.1. Preliminary experiments
The results concerning the changes in plasma levels of NOx,
XB2 and PGI2 obtained with the compounds under inves-
igation are reported in Table 1. Naproxen, at the maximal
ose used (50 mg kg−1), reduced by 89% (P < 0.001) and 71%
P < 0.001) the amount of blood TXB2 and PGI2, respectively,
ut it was devoid of any activity on NOx concentration. Defi-
rotide dose-dependently increased plasma PGI2, and this effect
as marked at 200 mg kg−1 (15.1-fold increment; P < 0.001).
t this dose, defibrotide reduced TXB2 (−52%; P < 0.001) and
ncreased NOx (2.5-fold; P < 0.001). Nitro-naproxen did not
nfluence the levels of PGI2 in the circulation at all doses used.
owever, at the dose of 80 mg kg−1, this compound markedly
educed TXB2 (−75%; P < 0.001) and increased NOx (4.4-fold;
< 0.001). ISDN (40 mg kg−1) and l-arginine (25 mg kg−1)
esulted equally effective in increasing the NOx concentration
n the blood. At these doses, the amount of NOx was increased
.6-fold (P < 0.001) and 5.4-fold (P < 0.001), respectively, as
ompared to that found in vehicle-treated rats. Furthermore, both
SDN and l-arginine significantly reduced the levels of plasma
XB2 and this event was associated with an increase in plasma
GI2.
.2. Myocardial ischemia/reperfusion in anaesthetized rats
.2.1. Hemodynamics
The hemodynamic parameters measured in anaesthetized
ats just before LCA-occlusion and treated orally with
ehicle (PEG 400; 2 ml kg−1), naproxen (50 mg kg−1),
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Table 2
Hemodynamic parameters measured in anaesthetized rats immediately before coronary artery occlusion
Treatment MAP (mmHg) HR (b min−1) LVSP (mmHg) LVEDP (mmHg) LVdP/dtmax (mmHg s−1) PRI (mmHg min−1 × 103)
Vehicle (n = 25) 105 ± 6 406 ± 19 135 ± 7 5.3 ± 0.3 5095 ± 207 42.4 ± 1.2
Naproxen (n= 18) 107 ± 4 411 ± 21 134 ± 7 5.3 ± 0.5 5178 ± 206 43.7 ± 1.3
Defibrotide (n= 17) 103 ± 3 409 ± 18 136 ± 6 5.0 ± 0.4 5095 ± 273 44.5 ± 0.9
Nitro-naproxen (n= 18) 106 ± 4 417 ± 17 131 ± 6 5.4 ± 0.4 4926 ± 365 42.7 ± 0.9
ISDN (n= 19) 85 ± 3* 435 ± 25 108 ± 4* 6.1 ± 0.6 4797 ± 189 39.4 ± 1.4
l-Arginine (n= 19) 102 ± 8 424 ± 20 120 ± 5 6.0 ± 0.5 5035 ± 187 42.9 ± 0.6
Vehicle (PEG 400, 2 ml kg−1), naproxen (50 mg kg−1), defibrotide (200 mg kg−1), nitro-naproxen (80 mg kg−1), isosorbide dinitrate (ISDN, 40 mg kg−1) and l-
arginine (25 mg kg−1) were administered orally once a day for 5 consecutive days. In brackets, number of experiments. Data are expressed as mean ± S.E.M. MAP,
mean arterial pressure; HR, heart rate; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; LVdP/dtmax , maximal velocity rate
of pressure development of left ventricle.
* P < 0.05 vs. vehicle-treated rats.
defibrotide (200 mg kg−1), nitro-naproxen (80 mg kg−1), ISDN
(40 mg kg−1) or l-arginine (25 mg kg−1) for 5 consecutive days
are reported in Table 2. At variance with ISDN, the values
related to MAP and HR were all in the same range, and the
values concerning cardiac mechanics (LVSP, LVEDP, LVDevP,
LVdP/dtmax and PRI) did not show statistical differences. Fol-
lowing LCA-occlusion, the MAP-values of all the experi-
mental animals fell consistently and abruptly (peak effect at
5–6 min) and then it progressively recovered within 30 min to
95–100 mmHg (data not shown).
3.2.2. Arrhythmia and mortality rate
When LCA was occluded in vehicle-treated rats, a consistent
ventricular arrhythmias was observed. These events persisted
significantly during reperfusion and it was associated with a rel-
evant mortality rate (Table 3). During the 30 min of regional
myocardial ischemia the VPBs recorded were 1547 ± 139 and
the incidence of VT and VF was 100% and 61%, respectively.
The dysrhythmias during the reperfusion period consisted of
303 ± 40 VPBs with an incidence of VT and VF of 47% and
12%, respectively. The total mortality rate in this group of 25
vehicle-treated animals submitted to MI/R was marked as being
36% (P < 0.001). Treatment of the rats submitted to MI/R with
the compounds under investigation brought about protection
against ventricular ectopic activity and reduction in mortality
rate. Among them, the PGI2-releaser defibrotide showed the
highest antiarrhythmic effect during both the ischemic and reper-
fusion periods and all the animals in this group survived through-
out the experiment. The rank order of potency in reducing the
mortality rate was defibrotide ≥ l-arginine > nitro-naproxen and
ISDN > naproxen ((Table 3).
3.2.3. Infarct size
The results obtained from the evaluation of the infarct size in
rats submitted to MI/R are reported in Table 4. The mean values
of the area at risk, expressed as a percentage of left ventricular
wall, was similar in all animal groups studied. In vehicle-treated
rats, LCA-occlusion for 30 min followed by 120 min reperfu-
sion resulted in an infarct size of 64.5 ± 4.6% of the area at risk.
Treatment of the animals with the compounds under investiga-
tion gave rise to a reduction of the infarct size as compared with
that obtained in vehicle-treated animals. Defibrotide was the
most effective since it reduced the infarct size of 13.8 ± 2.2%
of the area at risk, which is 4.7-fold inferior (P < 0.001) to that
determined in vehicle-treated rats. The rank order of potency
of the remaining compounds under investigation in preventing
the progression of ventricular necrosis was l-arginine ≥ nitro-
naproxen > ISDN > naproxen (Table 4).
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roups Arrhythmias during occlusion
VPBs (total) VT (% inc) V
ham (n = 14) 0 0 0
ehicle + MI/R (n = 16) 1547 ± 1139 100 61
aproxen + MI/R (n = 14) 1010 ± 82* 74 40
efibrotide + MI/R (n = 17) 362 ± 76*** 26 10
itro-naproxen + MI/R (n = 16) 642 ± 51** 40 18
SDN + MI/R (n = 17) 775 ± 78** 48 26
-Arginine + MI/R (n = 18) 507 ± 62*** 34 14
ehicle (PEG 400, 2 ml kg−1), naproxen (50 mg kg−1), defibrotide (200 mg kg
rginine (25 mg kg−1) were administered orally once a day for 5 consecutive da
ham-operated animals treated with vehicle; VPBs, ventricular premature (ectop
f incidence.
* P < 0.05 vs. vehicle + MI/R group.
** P < 0.01 vs. vehicle + MI/R group.
** P < 0.001 vs. vehicle + MI/R group.followed by 120 min of reperfusion (MI/R)
Arrhythmias during reperfusion Mortality
inc) VPBs (total) VT (% inc) VF (% inc) %
0 0 0 0
303 ± 40 47 12 36.0
192 ± 15* 30 8 22.2*
28 ± 8*** 4 0 0***
111 ± 23** 14 4 11.1**
108 ± 18** 12 0 10.5**
75 ± 10*** 10 0 5.3**
nitro-naproxen (80 mg kg−1), isosorbide dinitrate (ISDN, 40 mg kg−1) and l-
ta are expressed as mean ± S.E.M. In brackets, number of experiments. Sham,
ats; VT, ventricular tachycardia; VF, ventricular fibrillation; % inc, percentage
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Table 4
Heart weight/body weight (HW/BW), left ventricle weight (LVW), area at risk (AAR) and infarct size in rats subjected to 30 min of coronary artery occlusion
followed by 120 min of reperfusion (MI/R)
Groups HW/BW (mg g−1) LVW (mg) AAR (% of LVW) Infarct size (% of AAR)
Sham (n = 14) 2.99 ± 0.10 515 ± 32 n.d. n.d.
Vehicle + MI/R (n = 16) 3.07 ± 0.08 504 ± 27 54.4 ± 2.5 64.5 ± 4.6
Naproxen + MI/R (n = 14) 3.12 ± 0.13 527 ± 33 54.2 ± 3.1 47.9 ± 3.8*
Defibrotide + MI/R (n = 17) 3.05 ± 0.11 498 ± 36 55.7 ± 3.4 13.8 ± 2.2***
Nitro-naproxen + MI/R (n = 16) 2.97 ± 0.12 533 ± 25 53.1 ± 3.3 29.2 ± 3.7***
ISDN + MI/R (n = 17) 3.06 ± 0.09 522 ± 30 53.3 ± 3.5 32.6 ± 4.8**
l-Arginine + MI/R (n = 18) 3.09 ± 0.14 497 ± 51 55.0 ± 2.8 20.3 ± 2.6***
Vehicle (PEG 400, 2 ml kg−1), naproxen (50 mg kg−1), defibrotide (200 mg kg−1), nitro-naproxen (80 mg kg−1), isosorbide dinitrate (ISDN, 40 mg kg−1) and l-
arginine (25 mg kg−1) were administered orally once a day for 5 consecutive days. In brackets, number of experiments. Data are expressed as mean ± S.E.M. Sham,
sham-operated animals treated with vehicle. n.d., not detectable.
* P < 0.05 vs. vehicle + MI/R group.
** P < 0.01 vs. vehicle + MI/R group.
*** P < 0.001 vs. vehicle + MI/R group.
Table 5
Cardiac myeloperoxidase (MPO) and plasma creatine phosphokinase (CPK) activities measured in rats subjected to 30 min of coronary artery occlusion followed by
120 min of reperfusion (MI/R)
Groups Cardiac MPO (U/g tissue) Plasma CPK (U/l)
Area not at risk Area at risk 0 min (Pre-occlusion) 30 min (End-occlusion) 150 min (End-reperfusion)
Sham (n = 14) 0.45 ± 0.08 n.d. 242 ± 30 291 ± 27 321 ± 37
Vehicle + MI/R (n = 16) 0.43 ± 0.05 5.01 ± 0.43# 260 ± 27 934 ± 33 2012 ± 108
Naproxen + MI/R (n = 14) 0.39 ± 0.07 3.94 ± 0.27* 239 ± 12 702 ± 44* 1564 ± 75*
Defibrotide + MI/R (n = 17) 0.42 ± 0.05 0.72 ± 0.16*** 221 ± 32 355 ± 38*** 535 ± 46***
Nitro-naproxen + MI/R (n = 16) 0.37 ± 0.03 2.32 ± 0.14** 257 ± 25 527 ± 52** 1023 ± 51**
ISDN + MI/R (n = 17) 0.41 ± 0.09 2.11 ± 0.20** 238 ± 32 453 ± 24** 904 ± 71**
l-Arginine + MI/R (n = 18) 0.43 ± 0.07 1.85 ± 0.24*** 251 ± 30 405 ± 28*** 701 ± 52***
Vehicle (PEG 400, 2 ml kg−1), naproxen (50 mg kg−1), defibrotide (200 mg kg−1), nitro-naproxen (80 mg kg−1), isosorbide dinitrate (ISDN, 40 mg kg−1) and l-
arginine (25 mg kg−1) were administered orally once a day for 5 consecutive days. In brackets, number of experiments. Data are expressed as mean ± S.E.M. In
brackets, number of experiments. Sham, sham-operated animals treated with vehicle; n.d., not detectable.
# P < 0.001 vs. sham.
* P < 0.05 vs. vehicle + MI/R group.
** P < 0.01 vs. vehicle + MI/R group.
*** P < 0.001 vs. vehicle + MI/R group.
3.2.4. Cardiac MPO and plasma CPK activities
The results of cardiac MPO and plasma CPK enzymes related
to all animal groups are reported in Table 5. In vehicle-treated
rats the mean values of MPO activity obtained in the area not at
risk of the left ventricular wall was low and not significantly dif-
ferent among the seven experimental groups (from 0.37 ± 0.03
to 0.45 ± 0.08 U g−1 tissue). On the contrary these values deter-
mined in the area at risk of vehicle-treated animals increased
11.7-fold (P < 0.001) as compared to that obtained in the area
not at risk, indicating infiltration and activation of inflamma-
tory cells such as neutrophils in the jeopardized ventricular
tissue. Treatment of the rats with the compounds under inves-
tigation resulted in a reduction of MPO activity in the area at
risk of different degree with a maximal activity for the PGI2-
releaser defibrotide. However, the rank order in the control of
MPO enzymes is: defibrotide ≥ l-arginine > ISDN and nitro-
naproxen > naproxen. In Table 5 results concerning plasma CPK
activity are reported. In vehicle-treated rats it increased 7.7-fold
(P < 0.001) at the end of reperfusion period, being this value
260 ± 27 U l−1 before coronary occlusion. Among the com-
pounds used in this study, defibrotide was the most effective
in the control of plasma CPK activity. The rank order in the con-
trol of plasma CPK activity is: defibrotide ≥ l-arginine > ISDN
and nitro-naproxen > naproxen.
4. Discussion
The results obtained with the present study clearly indicate
that nitro-naproxen, ISDN, l-arginine and defibrotide provide
a substantial cardioprotection when given orally for 5 consecu-
tive days to rats submitted to a marked insult of 30-min regional
myocardial ischemia and 120-min reperfusion. The beneficial
effects disclosed by these compounds are evident in the pre-
vention of cardiac and biochemical abnormalities observed in
vehicle-treated rats. The occurrence of VPBs was noticeably
reduced and this was strictly correlated with the high inci-
dence of the survived animals and the reduction of infarct size.
This may be explained by the results obtained with prelimi-
nary experiments showing a significant increase of NOx-levels
in nitro-naproxen, ISDN and l-arginine treated animals. This
indicates that NO availability was first augmented, broken dawn
in nitrite, and subsequently oxidized to nitrate by red blood cells
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[29,30]. A small but a significant increase in blood PGI2 concen-
tration was also observed in these experiments with both ISDN
and l-arginine. This may be due to a direct interaction of NO and
cyclooxygenase to cause stimulation of enzyme activity [31,32].
In this respect, the cyclooxygenase enzymes are a potential target
for NO because they contain an iron-heme center at their active
site [19]. However, with defibrotide the remarkable increase of
PGI2 production may have played a prominent role in the cardio-
protection observed during ischemia-reperfusion. The basal lev-
els of blood TXB2 were also reduced by various degrees. These
data may support the concept that the well-known prothrom-
botic effect of this autacoid may have been antagonized during
the ischemic insult by the current assets of NO and PGI2 in the
circulation caused by the four compounds under investigation.
The control of ventricular necrosis extension in rats submitted
to ischemia-reperfusion obtained with nitro-naproxen, ISDN,
l-arginine and particularly defibrotide is corroborated by a sig-
nificant reduction of plasma CPK and MPO activity in the area
at risk of the ventricular wall. A number of events can lead
to the enhanced MPO activity such as adherence of polymor-
phonuclear leukocytes to vascular endothelial cells. With regard
to this point, it has been already shown that cardiac necrosis
can be significantly attenuated by treatment with NO-donors,
an organic NO-donor and l-arginine or by specific blockers
of adhesion molecules, particularly P-selectin [33,34]. Neu-
trophils have been implicated as a primer mechanism underlying
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tion of ventricular filling pressure, augmentation of collateral
coronary flow and inhibition of platelet aggregation, may have
contributed to restrain infarct size. However, excessive produc-
tion of NO during ischemia-reperfusion has been shown to cause
myocardial injury where peroxinitrite-increased generation is
involved [41]. On this ground, Parlakpinar et al. [42] and Sahna
et al. [43] demonstrate that inhibition of inducible NO synthase
with aminoguanidine reduced NO’s side effect in ischemia-
reperfusion damage. Although the role of NO in the progression
of myocardial infarction is controversial [44,45], the present
results are in line with most other studies supporting the idea that
NO mimicry/supplementation limits infarct size and production
of dysrhythmias [46,47]. The results obtained with naproxen,
which are in agreement with those recorded with aspirin in
the same experimental procedure [10], suggest that blockade
of TXB2 formation is not sufficient to provide cardioprotection
particularly when in parallel PGI2 generation is inhibited. Recent
data indicate that chronic use of traditional NSAIDs is associated
with risk of non-fatal myocardial infarction in the general popu-
lations [48]. Particularly, in healthy subject, naproxen appears to
interfere with the effect of aspirin on cyclooxygenase-1 (COX-
1) activity and function, under miming the sustained inhibition
of COX-1 in platelets [49].
Although, experimental conditions adopted in the present
study are very different from the clinical situation, where pre-
treatment is most often not possible and where ischemia-periods
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Rschemic-reperfusion injury and cardiac necrosis progression.
he propensity to injure the myocardium and its component
ells, notably coronary vascular endothelium, microvasculature
nd myocytes, stems from the myocardium’s primary responses
o inflammatory mediators which lead to a redirection of a nor-
al inflammatory response. The process involved in inducing
issue injury by neutrophils includes free radical generation and
elease of proteases, and other proinflammatory mediators [35].
The relevant increase of PGI2, in the circulation such as
hat obtained with defibrotide (15-fold as compared to vehicle-
reated animals) should be considered a key point in limitat-
ng polymorphonuclear leukocytes activation during ischemia-
eperfusion. In fact, it has been already proved that, in perfused
abbit heart with human polymorphonuclear leukocytes under
ecirculating conditions, defibrotide, via PGI2 release, prevents
eukocyte–vascular wall interaction and inhibits sulfidopeptide
eukotrienes generation [36]. These lipidic mediators affect the
ajor component of the cardiovascular system, i.e. they can con-
trict small and large coronary vessels, thus contributing to the
anifestations of ischemia-reperfusion damage [37,38].
On the other end, the increased availability of NO provided
y nitro-naproxen, ISDN and l-arginine, is of paramount impor-
ance in cardioprotection since NO has been shown to reduce
olymorphonuclear leukocytes-mediated endothelial dysfunc-
ion in myocardial ischemia-reperfusion, and this is very likely
o have happened because of a specific interaction with adhesion
olecules [39]. NO may also affect reperfusion and reoxige-
ase injury by augmenting coronary dilation and coronary blood
ow reducing leukocyte and platelet interaction with vascular
ndothelium and scavenging superoxide radicals [40]. Further-
ore, other known physiological effects of NO, such as reduc-re frequently more protracted, the results obtained further
mphasize that the increase of both NO and PGI2 in the cir-
ulation brings about an orchestrated sequence of cellular and
olecular events which lead to a limitation of myocardial dam-
ge ensuing from ischemia-reperfusion.
In conclusion, for patients who needs an adequate control
f cardiovascular risk factors, the therapeutic management with
ompounds that insure a good balance between NO/PGI2 pro-
uction and TXB2 inhibition represent a favorable option.
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